Skip to main content

Or 34,00 After 66% tax deduction

I make a monthly donation I make an IFI donation
Research, science & health

Gene therapy : regulate the expression of a gene through a specific diet

Published on: 14/06/2016 Reading time: 1 min
Thérapie génique
Retour à la recherche

Basic research in the field of nutrition has enabled to develop, in animals, a system regulating the expression of a gene through a specific diet leading to original therapeutic applications. Developed by a team from the Human Nutrition Unit (Inra, University of Auvergne), in collaboration with researchers of the Brain and Spine Institute (CNRS, Inserm, AP-HP, UPMC), this tool allows to monitor the expression of a therapeutic protein, and disseminate it locally and intermittently according to needs. These results were recently published in Nature Biotechnology magazine.

Gene therapy consists in the introduction of a gene within cells to treat or prevent diseases. This gene can replace a defective gene in the case of a genetic disease or favour the production and local dissemination of a therapeutic factor. A major limitation in the use of gene therapy is the lack of control of transgene regulation (the gene introduced in the body). The only inducible systems in mice require the expression of exogenous regulatory proteins (receptors) as well as inducing chemical molecules (doxycycline, ecdysone, rapamycin...). However, the potential side effects of these systems preclude their use in human medicine.

The "gene-nutrient" team from the human nutrition Unit (Inra, University of Auvergne), in collaboration with the "Biotechnology and Biotherapy" team from the Institut du Cerveau - ICM (CNRS, Inserm, APHP, UPMC) has developed a system in which the regulation of a gene is controlled through a special diet, in which one of the essential amino acids (EAA) is absent.

In mammals, EAAs are not synthesized by the body and must be provided by food. In case of deficit, the body must adapt to the deficit in EAA. To do so, it activates a specific signalling pathway leading to the regulation of the production of certain proteins involved in amino acid homeostasis. Researchers have thus used the properties of this signalling pathway in order to develop a regulation system consisting in a promoter (DNA area, allowing the transcription and thus the expression of a gene) and an inducer*. In this system, scientists are able to control the activation of the promoter through ingestion of a diet deficient in EAA**.

As a first step, researchers have tested the induction of a "reporter" gene (test) in mice. The construction has been transferred to different tissues : liver, pancreas, or in a particular area of the brain, the hippocampus. They have found that a meal devoid of EAA induced very quickly the expression of the transgene. They have thereafter evaluated the efficiency of a therapeutic gene against cancer : TRAIL. The expression of this gene leads to tumour cell death. However, this expression has to be highly localized on the tumour site and very finely regulated, since it is potentially toxic to normal human cells in case of strong and prolonged exposure. Researchers have shown the possibility of an intermittent and controlled regulation of the expression of TRAIL and its effect on tumour proliferation inhibition.

The discovery of a simple, reliable and safe way to regulate the expression of genes is a crucial step forward in the field of gene therapy and its multiple fields of application. Indeed, the gene-drug expression often requires an accurate regulation and an exact dosage. This system will allow gene therapy treatments which could not be considered before.

* The promoter is, among other elements, constituted of answers to amino acids and the inducer is the amino acid deficient diet.

** Such a diet should be administered after a short fast and has to be provided in the form of a free amino acid "cocktail" or a full meal in which proteins are replaced by a free amino acid mixture.

Sources

Regulating the expression of therapeutic transgenes by controlled intake of dietary essential amino acids. Cédric Chaveroux, Alain Bruhat, Valérie Carraro, Céline Jousse, Julien Averous, Anne-Catherine Maurin, Laurent Parry, Florent Mesclon, Yuki Muranishi, Pierre Cordelier, Aline Meulle, Patrick Baril, Anh Do Thi, Philippe Ravassard, Jacques Mallet & Pierre Fafournoux. Nature Biotechnology, 6 juin 2016.
http://www.ncbi.nlm.nih.gov/pubmed/27272383

Our news on the subject

Sclérose en plaques : identification d’une nouvelle molécule favorisant la remyélinisation
Multiple Sclerosis: Identification of a Molecule that Promotes Repair of the Nervous System
A molecule previously studied in the context of sleep disorders and attention deficit hyperactivity disorder (ADHD) is now, for the first time, revealing its potential in experimental models of multiple sclerosis (MS): it protects neurons and...
01.27.2026 Research, science & health
VignetteActu WBHF 2026
World Brain Health Forum 2026
More than one in three people will experience a brain disorder at some point in their lives. This reality, identified by the World Health Organization as a major public health priority, calls for unprecedented international mobilization. It is...
01.12.2026 Events
Une nouvelle approche pour évaluer les patients en état de conscience altérée
A New Approach to Assessing Patients with Disorders of Consciousness
In intensive care units, some patients who appear unconscious occupy a gray zone in their relationship to the world. To better diagnose them and predict their recovery potential, Dragana Manasova, Jacobo Sitt, and their colleagues have developed an...
01.08.2026 Research, science & health
Ne plus penser à rien : vers une signature cérébrale du blanc mental
Not Thinking About Anything: Toward a Brain Signature of Mind Blanking
What if the flow of our thoughts occasionally just stopped? Esteban Munoz-Musat, Lionel Naccache, Thomas Andrillon, and their colleagues at Paris Brain Institute and Monash University in Melbourne show that the sensation of “thinking about nothing”...
12.26.2025 Research, science & health
Deux nouvelles certifications pour les plateformes de l’Institut du Cerveau
Two new certifications for Paris Brain Institute’s core facilities
Paris Brain Institute’s core facilities were recently awarded two new certifications: ISO 9001 certification for ICM.Quant and ISO 20387 certification for its DNA & Cell Bank.
11.14.2025 Institutional
La dépression résistante possède une signature moléculaire spécifique
Treatment-resistant depression identified as a distinct molecular subtype
An international study published in Brain, Behavior, and Immunity shows that patients with treatment-resistant depression (TRD) have a unique biology, different from those who respond to standard therapies. More than 5,000 genes were found to behave...
11.03.2025 Research, science & health
See all our news